07.02.2024 14:00:49
|
REGENXBIO Reports Positive Results From Phase I/II AFFINITY DUCHENNE Trial
(RTTNews) - REGENXBIO Inc. (RGNX) Wednesday reported additional positive results from the Phase I/II AFFINITY DUCHENNE trial of RGX-202 in patients with Duchenne muscular dystrophy.
The Phase I/II AFFINITY DUCHENNE trial is designed to evaluate the safety, tolerability and clinical efficacy of a one-time intravenous (IV) dose of RGX-202 in patients with Duchenne.
As per new data, a patient aged 6.6 years old, who received RGX-202 at dose level 1, had microdystrophin expression level at 83.4% of control at three months. A reduction from baseline in serum creatinine kinase (CK) levels of 93% was observed at ten weeks.
The company said it is on track to initiate pivotal trial in second half of 2024.
REGENXBIO shares are up more than 14% in pre-market. The stock had closed at $13.05, up 5.93% on Tuesday. It has traded in the range of $11.83 - $25.32 in the last 1 year.
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu REGENXBIO Incmehr Nachrichten
05.11.24 |
Ausblick: REGENXBIO legt Zahlen zum jüngsten Quartal vor (finanzen.net) | |
31.07.24 |
Ausblick: REGENXBIO vermeldet Zahlen zum jüngsten Quartal (finanzen.net) |
Analysen zu REGENXBIO Incmehr Analysen
Aktien in diesem Artikel
REGENXBIO Inc | 8,00 | 0,63% |